News
Published over 13 years ago. See the latest and most current information on News.
ICON plc (Dublin), a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, and Korea National Enterprise for Clinical Trials (KoNECT) have signed a partnership agreement that aims to advance the clinical trials industry in South Korea.
Through the agreement, ICON and KoNECT will collaborate on a series of educational events for local and multinational pharmaceutical companies, investigators and industry officials.
“South Korea has become a key country for clinical development and ICON has had a well-established presence there since 2005,” commented Wei Ming Goh, ICON’s Vice President, Asia-Pacific.
“Our agreement with KoNECT supports our mutual interest in developing and growing the clinical research industry in South Korea and demonstrates our on-going commitment to the Asia Pacific region.”
KoNECT President, Professor Sang-Goo Shin, added, “We are delighted to collaborate with a leading clinical research organisation such as ICON that has a wealth of expertise in both local and global clinical development programmes. Together we can develop high quality clinical research professionals and a clinical trials infrastructure that can support the increased demand from local and global pharma companies."
ILM Guide 2026/27